These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16292351)

  • 1. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.
    Le LP; Rivera AA; Glasgow JN; Ternovoi VV; Wu H; Wang M; Smith BF; Siegal GP; Curiel DT
    Gene Ther; 2006 Mar; 13(5):389-99. PubMed ID: 16292351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
    Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
    Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenoviral therapy in gallbladder carcinoma.
    Tekant Y; Davydova J; Ramirez PJ; Curiel DT; Vickers SM; Yamamoto M
    Surgery; 2005 May; 137(5):527-35. PubMed ID: 15855925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma.
    Zheng S; Ulasov IV; Han Y; Tyler MA; Zhu ZB; Lesniak MS
    J Gene Med; 2007 Mar; 9(3):151-60. PubMed ID: 17351980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
    Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
    Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
    Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
    J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.
    Zhu ZB; Mathis JM; Makhija SK; Lu B; Wang M; Ji S; Rivera AA; Rosenthal EL; Siegal GP; Curiel DT
    Int J Oncol; 2007 Nov; 31(5):1213-22. PubMed ID: 17912450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
    Graat HC; Witlox MA; Schagen FH; Kaspers GJ; Helder MN; Bras J; Schaap GR; Gerritsen WR; Wuisman PI; van Beusechem VW
    Br J Cancer; 2006 Jun; 94(12):1837-44. PubMed ID: 16736005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.
    Zhu ZB; Chen Y; Makhija SK; Lu B; Wang M; Rivera AA; Yamamoto M; Wang S; Siegal GP; Curiel DT; McDonald JM
    Int J Oncol; 2006 Nov; 29(5):1319-29. PubMed ID: 17016667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model.
    Nagayama Y; Nakao K; Mizuguchi H; Hayakawa T; Niwa M
    Gene Ther; 2003 Aug; 10(16):1400-3. PubMed ID: 12883537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
    Hoffmann D; Meyer B; Wildner O
    J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.